Jodie P. Morrison
CEO, Cadent Therapeutics
Morrison is also a member of Cadent's board of directors. Previously, she was interim CEO at Keryx Bioppharmaceuticals Inc. , leading to the merger with Akebia Therapeutics, and acting COO at Syntimmune, acquires by Alexion. Earlier whe served as president and CEOI of Tokai Pharmaceuticals Inc.
- October 2020
Added to: Ribon Therapeutics - Cambridge, MA
Ribon Therapeutics is a clinical state biotechnology company developing therapeutics targeting novel enzyme families that contribute to disease. Their lead program is an inhibitor in development for the treatment of cancer.